Blaze Bioscience Inc.
8
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
2 terminated/withdrawn out of 8 trials
71.4%
-15.1% vs industry average
0%
0 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
Role: collaborator
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
Role: collaborator
Expanded Access for BLZ-100 (Tozuleristide)
Role: lead
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
Role: lead
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
Role: lead
Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery
Role: lead
Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery
Role: lead
Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery
Role: lead
All 8 trials loaded